CompletedPhase 1NCT05187546
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
Studying Classic progressive supranuclear palsy syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Life Molecular Imaging GmbH
- Principal Investigator
- Andrew Stephens, MD, PhDLife Molecular Imaging
- Intervention
- [18F]-PI2620(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 50-80 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- Ludwig-Maximilians-Universität München, Munich, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05187546 on ClinicalTrials.govOther trials for Classic progressive supranuclear palsy syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07509125Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic DisordersUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGEARLY PHASE1NCT07348276First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the BrainInvicro
- RECRUITINGNANCT07291687tDCS as Treatment for Motor FunctionBaycrest
- ACTIVE NOT RECRUITINGNANCT06588673Art Therapy in Progressive Supranuclear PalsyVanderbilt University Medical Center
- ENROLLING BY INVITATIONNANCT06597071Parkinson Atypical Rating of Oculometric Patterns Evaluated RoutinelyNeuraLight
- ACTIVE NOT RECRUITINGPHASE2NCT06355531A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)Ferrer Internacional S.A.
- RECRUITINGNCT06949865AI-Enhanced Optimization of Acute Levodopa Challenge TestBeijing Tiantan Hospital
- RECRUITINGNANCT06174948The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related DisordersQueen Mary University of London
See all trials for Classic progressive supranuclear palsy syndrome →